Waverly Advisors LLC grew its holdings in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 98.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,733 shares of the medical device company’s stock after acquiring an additional 27,150 shares during the period. Waverly Advisors LLC’s holdings in DexCom were worth $3,437,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also modified their holdings of DXCM. Renaissance Technologies LLC raised its position in DexCom by 9.6% in the 1st quarter. Renaissance Technologies LLC now owns 1,582,996 shares of the medical device company’s stock valued at $99,412,000 after purchasing an additional 138,200 shares in the last quarter. Gabelli Funds LLC grew its position in shares of DexCom by 22.1% during the first quarter. Gabelli Funds LLC now owns 61,300 shares of the medical device company’s stock worth $3,850,000 after buying an additional 11,100 shares in the last quarter. Public Employees Retirement System of Ohio increased its stake in shares of DexCom by 48.5% during the first quarter. Public Employees Retirement System of Ohio now owns 176,637 shares of the medical device company’s stock worth $11,093,000 after buying an additional 57,722 shares during the period. Compound Planning Inc. increased its stake in shares of DexCom by 33.1% during the first quarter. Compound Planning Inc. now owns 4,283 shares of the medical device company’s stock worth $269,000 after buying an additional 1,066 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its holdings in DexCom by 100.4% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,545,103 shares of the medical device company’s stock valued at $159,832,000 after acquiring an additional 1,275,142 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.
DexCom Stock Up 0.4%
DexCom stock opened at $75.14 on Thursday. The company has a market capitalization of $28.99 billion, a P/E ratio of 32.11, a PEG ratio of 1.23 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The stock has a 50-day simple moving average of $72.86 and a 200-day simple moving average of $69.05.
Insider Buying and Selling
In other news, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director directly owned 25,007 shares of the company’s stock, valued at $1,500,670.07. The trade was a 3.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of DexCom stock in a transaction on Monday, June 15th. The shares were sold at an average price of $74.13, for a total transaction of $296,520.00. Following the completion of the transaction, the director owned 52,852 shares in the company, valued at approximately $3,917,918.76. This represents a 7.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 98,506 shares of company stock valued at $7,205,258 in the last 90 days. Company insiders own 0.28% of the company’s stock.
Analysts Set New Price Targets
DXCM has been the subject of several analyst reports. Citigroup reiterated a “buy” rating and set a $84.00 price target (up from $79.00) on shares of DexCom in a report on Thursday, May 28th. Deutsche Bank Aktiengesellschaft started coverage on shares of DexCom in a report on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price objective on the stock. Benchmark reaffirmed a “buy” rating on shares of DexCom in a research report on Tuesday, June 23rd. Raymond James Financial reiterated a “strong-buy” rating and set a $91.00 target price on shares of DexCom in a research note on Monday, June 8th. Finally, Piper Sandler reissued an “overweight” rating and issued a $88.00 target price (up from $75.00) on shares of DexCom in a report on Monday, June 15th. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $85.40.
Read Our Latest Report on DXCM
DexCom Profile
DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.
Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.
Read More
- Five stocks we like better than DexCom
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
